Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 27Observational 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Prostatic Hyperplasia 2Neoplasms 1

Interventions

Surveys and Questionnaires 34Blood Specimen Collection 24enzalutamide 18Radiotherapy 15Docetaxel 15Biopsy 14Abiraterone Acetate 14apalutamide 13Leuprolide 13Interviews as Topic 13Observation 12Magnetic Resonance Spectroscopy 12Watchful Waiting 10radium Ra 223 dichloride 9darolutamide 9Androgen Antagonists 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Radiosurgery 7Magnetic Resonance Imaging 7Brachytherapy 7abiraterone 6Specimen Handling 6Amplified Fragment Length Polymorphism Analysis 6Triptorelin Pamoate 5Standard of Care 5Positron Emission Tomography Computed Tomography 5Gonadotropin-Releasing Hormone 5Focus Groups 5Registries 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Prostatic Neoplasms × Dutasteride × Clear all
NCT01594502 2020-10-12

Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

University of Illinois at Chicago

Completed
139 enrolled
Genitourinary

Prostatic Neoplasms

NCT00883909 2017-07-11

ARI103094-Follow-Up Study for REDUCE Study Subjects

GlaxoSmithKline

Completed
2,795 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT01337258 2017-05-30

Economic Analyses of the REDUCE Trial

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

NCT01525914 2012-02-03

Response of Patients on Surveillance for Prostate Cancer to Dutasteride

Sunnybrook Health Sciences Centre

Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡